Global Blood Therapeutics Quick Ratio (GBT) starting from the second quarter 2022 to second quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Global Blood Therapeutics Inc.  (NASDAQ: GBT)

Global Blood Therapeutics's Quick Ratio

GBT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2022, Quick Ratio fell to 5.56 below Global Blood Therapeutics Inc. average.

Within Major Pharmaceutical Preparations industry 276 other companies have achieved higher Quick Ratio than Global Blood Therapeutics in second quarter 2022. While Quick Ratio total ranking in the second quarter 2022 has deteriorated compared to the prior quarter from 725 to 912.

Explain Quick Ratio?
How much Cash & cash equivalents GBT´s has?
What are GBT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GBT Quick Ratio (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3		 (Jun 30 2021)
Q2
Y / Y Current Liabilities Change 28.09 % 34.49 % 11.34 % -4.99 % 4.72 %
Y / Y Cash & cash equivalent Change 18.24 % 14.81 % 22.08 % -27.42 % -19.11 %
Quick Ratio MRQ 5.56 6.98 7.78 5.21 6.02
GBT's Total Ranking # 912 # 725 # 92 # 269 # 489
Seq. Current Liabilities Change 17.38 % -9.88 % 18.82 % 1.9 % 23.25 %
Seq. Cash & cash equivalent Change -6.55 % -19.18 % 77.35 % -11.73 % -9.26 %



Quick Ratio second quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 277
Healthcare Sector # 452
Overall Market # 912


Quick Ratio Statistics
High Average Low
24.11 12.18 5.21
(Sep 30 2015)   (Sep 30 2021)




Financial Statements
Global Blood Therapeutics's Current Liabilities $ 93 Millions Visit GBT's Balance sheet
Global Blood Therapeutics's Cash & cash equivalent $ 517 Millions Visit GBT's Balance sheet
Source of GBT's Sales Visit GBT's Sales by Geography


Cumulative Global Blood Therapeutics's Quick Ratio

GBT's Quick Ratio for the trailling 12 Months

GBT Quick Ratio

 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months		 (Jun 30 2021)
12 Months
Y / Y Current Liabilities TTM Growth 15.88 % 10.05 % 1.76 % -5.92 % 8.55 %
Y / Y Cash & cash equivalent TTM Growth 6.42 % -2.55 % -8.05 % -15.68 % -11.92 %
Quick Ratio TTM 6.4 6.56 6.78 6.55 6.97
Total Ranking TTM # 4996 # 4797 # 4991 # 4989 # 477
Seq. Current Liabilities TTM Growth 6.5 % 6.92 % 3.15 % -1.35 % 1.15 %
Seq. Cash & cash equivalent TTM Growth 3.87 % 3.59 % 6.63 % -7.25 % -4.88 %

Quick ratio ranking by company, industry and sector >> Back to GBT Financial Strength Comparisons >> Go to Compare GBT Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q2 2022 to $93.09 millions, cumulative Quick Ratio decreased to 6.4 below the Global Blood Therapeutics Inc. average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 581 other companies have achieved higher Quick Ratio than Global Blood Therapeutics. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2022 from 4797 to 4996.

Explain Quick Ratio?
How much Cash & cash equivalents GBT´s has?
What are GBT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 582
Healthcare Sector # 1150
Within the Market # 4996


trailing twelve months Quick Ratio Statistics
High Average Low
17.62 11.59 6.4
(Dec 31 2018)   (Jun 30 2022)




Companies with similar Quick Ratio in the quarter ending Jun 30 2022, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2022 MRQ Cash & cash equivalentJun 30 2022 MRQ Current Liabilities
Onkure Therapeutics Inc   15.22 $ 126.852  Millions$ 8.335  Millions
Liquidia Corporation  15.19 $ 103.840  Millions$ 6.837  Millions
Royalty Pharma Plc  15.15 $ 2,762.139  Millions$ 182.327  Millions
Lianbio  15.14 $ 329.299  Millions$ 21.747  Millions
Pyxis Oncology Inc   14.97 $ 223.355  Millions$ 14.916  Millions
Neurogene Inc   14.89 $ 117.429  Millions$ 7.886  Millions
Ayala Pharmaceuticals Inc   14.77 $ 28.150  Millions$ 1.906  Millions
Kronos Bio Inc   14.69 $ 267.889  Millions$ 18.230  Millions
Minerva Neurosciences Inc   14.60 $ 49.754  Millions$ 3.409  Millions
Keros Therapeutics Inc   14.59 $ 215.621  Millions$ 14.783  Millions
Centessa Pharmaceuticals Plc  14.42 $ 484.161  Millions$ 33.569  Millions
Igm Biosciences Inc   14.33 $ 513.205  Millions$ 35.817  Millions
Inozyme Pharma Inc   14.33 $ 151.480  Millions$ 10.573  Millions
Ataibeckley Inc   14.23 $ 312.486  Millions$ 21.957  Millions
Ventyx Biosciences Inc   14.17 $ 250.452  Millions$ 17.674  Millions
Context Therapeutics Inc   14.12 $ 42.921  Millions$ 3.040  Millions
Seres Therapeutics Inc   13.99 $ 195.795  Millions$ 13.992  Millions
Oragenics Inc   13.96 $ 17.867  Millions$ 1.280  Millions
Genprex Inc   13.95 $ 30.053  Millions$ 2.154  Millions
Immuron Limited  13.84 $ 15.267  Millions$ 1.103  Millions
Reata Pharmaceuticals Inc   13.75 $ 481.471  Millions$ 35.013  Millions
Tyme Technologies Inc.  13.72 $ 77.105  Millions$ 5.621  Millions
Histogen Inc   13.62 $ 12.598  Millions$ 0.925  Millions
Cryoport inc   13.59 $ 551.544  Millions$ 40.572  Millions
Entrada Therapeutics Inc   13.51 $ 244.254  Millions$ 18.077  Millions
Rocket Pharmaceuticals Inc   13.23 $ 321.368  Millions$ 24.289  Millions
Akouos inc   13.22 $ 192.895  Millions$ 14.590  Millions
Erasca Inc   13.12 $ 292.729  Millions$ 22.319  Millions
Alx Oncology Holdings Inc  13.08 $ 313.366  Millions$ 23.952  Millions
Cymabay Therapeutics Inc   13.05 $ 163.883  Millions$ 12.560  Millions

Date modified: 2026-08-30T17:12:36+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.